Experimental studies and controlled clinical testing of valproate and vigabatrin

Acta Neurologica Scandinavica

Volumn 78, Issue 4, 1988, Pages 241-270

  Gram, L ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

antiepileptic drugs; astrocytes; controlled trials; epilepsy; GABA; GABA transaminase; gamma vinyl GABA; neurons; review; valproate; vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ADULT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEIZURE;

AMINOCAPROIC ACIDS; ANIMAL; ANTICONVULSANTS; CLINICAL TRIALS; GAMMA-AMINOBUTYRIC ACID; HUMAN; RESEARCH DESIGN; SUPPORT, NON-U.S. GOV'T; VALPROIC ACID; VIGABATRIN;

EID: 0023771604     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1988.tb03655.x     Document Type: Review

References (196)

1. On the propyl derivatives and decomposition products of ethyl acetoacetate
2. Proprietes pharmacodynamiques de l'acide n‐diprophylacetique
3. y‐vinyl GABA (4‐amino‐hex‐5‐enoic acid), a new selective irreversible inhibitor of GABA‐T: effect on brain GABA metabolism in mice
4. Epilepsy and γ‐aminobutyric acid‐mediated inhibition
5. The role of γ‐aminobutyric acid in the mechanism of seizures
6. GABA and seizures: clinical correlates in man
7. Amino acid content of epileptogenic human brain: focal versus surrounding regions
8. Amino acid abnormalities in epileptogenic foci
9. Low cerebrospinal fluid γ‐aminobutyric acid content in seizure patients
10. Cerebrospinal fluid γ‐aminobutyric acid levels in children with different types of epilepsy: effect of anticonvulsant treatment
11. Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis
12. GABA in cerebrospinal fluid of children with febrile convulsions
13. Alterations of GABA‐mediated synaptic transmission in human epilepsy
14. Effect of diphenylhydantoin and adrenocortical steroids on free glutamic acid, glutamine, and gamma‐aminobutyric acid concentrations of rat cerebral cortex
15. Diphenylhydantoin prolongs postsynaptic inhibition and iontophoretic GABA action in the crayfish stretch receptor
16. Pentobarbital selectivity enhances GABA‐mediated postsynaptic inhibition in tissue cultured mouse spinal neurons
17. Interaction of barbiturates with dihydropicrotoxin in binding sites related to the GABA‐receptor‐ionophore system
18. Variation in the kinetic pattern of astrocytic γ‐aminobutyric acid uptake inhibited by different barbiturates
19. Antiepileptic drugs ‐ ben‐zodiazepines
20. GABA‐benzodiazepine‐barbiturate receptor interactions
21. Diazepam enhancement of low affinity GABA binding to rat brain membranes
22. Valproic acid augments GABA‐mediated postsynaptic inhibition in cultured mammalian neurons
23. Sodium di‐n‐propylacetate (valproate) potentiates responses to GABA and muscimol on single central neurons
24. Sodium valproate enhancement of γ‐aminobutyric acid (GABA) inhibition: electrophysiological evidence for anticonvulsant activity
25. Sodium valproate increases potassium in aplysia neurons
26. The presynaptic effects of valproic acid in the isolated frog spinal cord
27. Sodium valproate enhances responses to GABA receptor activation only at high concentrations
28. 14C]‐glucose into amino acids
29. Effect of n‐dipropylacetate on amino acid concentrations in mouse brain: correlation with anticonvulsant activity
30. On the mechanism of action of sodium valproate: the relationship of GABA and cyclic GMP levels to anticonvulsant activity
31. Electroen‐cephalographic and behavioural effects of a GABA agonist (Muscimol) on photosensitive epilepsy in the baboon Papio papio
32. GABA receptor‐agonists: relationship between structural and biological activity in vivo and in vitro.
33. THIP, a single blind controlled trial in patients with epilepsy
34. On the mode of action of SL 76002 a new GABA receptor agonist
35. Progabide: a controlled trial in partial epilepsy
36. Double‐blind crossover trial of progabide versus placebo in severe epilepsies
37. Progabide for refractory partial epilepsy: a controlled add‐on trial
38. Controlled study of progabide in partial seizures: methodology and results
39. GABA‐transaminase inhibitors and neuronal function
40. Convulsant drugs, anticonvulsant and GABA‐mediated neuronal inhibition
41. Uptake and metabolism of γ‐aminobutyric acid by neurons and glia cells
42. The in vivo inactivation of GABA and other inhibitory amino acids in the cat nervous system
43. Effect of GABA‐analogues on the high‐affinity uptake of GABA in astrocytes in primary culture
44. GABA uptake inhibitors: relevance to antiepileptic drug research
45. Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration
46. Transport and metabolism of γ‐aminobutyric acid in neurons and glia: implications for epilepsy
47. Tissue distribution, metabolism, anticonvulsant efficacy and effect on brain amino acid levels of the gliaselective γ‐aminobutyric acid transport inhibitor 4,5,6,7‐tetrahydroisoxazolo[4,5‐c]pyridin‐3‐ol in mice and chicks
48. Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions
49. The effect of sodium valproate on γ‐aminobutyrate metabolism and behaviour in naive and ethanolamine‐O‐sulphate pretreated rats and mice
50. Valproate‐induced changes in GABA metabolism at the subcellar level
51. Effect of chronic treatment with amino‐oxyacetic acid or sodium n‐dipropylacetate on brain GABA levels and the development and regression of cobalt epileptic foci in rats
52. Amino acid precursors: their transport into brain and initial metabolism
53. Compartmentation of glutamic acid metabolism in brain slices
54. A comparison of the biochemical effect of two catalytic inhibitors of mammalian brain GABA‐transaminase: γ‐vinyl GABA (amino‐4‐hex‐5‐enoic acid) and γ‐acetylenic GABA (amino‐4‐hex‐5‐ynoic acid)
55. The effect of 4‐aminohex‐5‐ynoic acid (γ‐acetylenic GABA, γ‐ethynyl GABA), a catalytic inhibitor of GABA‐transaminase, on brain GABA metabolism in vivo.
56. 4‐amino‐hex‐5‐enoic acid, a selective catalytic inhibitor of 4‐amino‐butyric‐acid aminotransferase in mammalian brain
57. γ‐vinyl GABA: effect of chronic administration on the metabolism of GABA and other amino compounds in rat brain
58. Audiogenic seizure protection by elevated brain GABA concentrations in mice: effect of γ‐acetylenic GABA and γ‐vinyl GABA, two irreversible GABA‐T inhibitors
59. Evidence for feedback regulation of glutamate decarboxylase by γ‐aminobutyric acid
60. Metabolic inhibitors and subcellular distribution of GABA
61. Effects of di‐n‐propylacetate, an anticonvulsive compound on GABA metabolism
62. An analysis of the kinetics of the inhibition of rabbit brain γ‐aminobutyrate aminotransferase by sodium n‐dipropylacetate and some other simple carboxylic acids
63. Di‐n‐pro‐pylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA‐transaminase
64. The inhibitory effect of sodium n‐dipropyl acetate on the degradative enzymes of the GABA shunt
65. Anticonvulsant action of ethanolamine‐O‐sulphate and di‐n‐propylacetate and the metabolism of γ‐aminobutyric acid (GABA) in mice with audiogenic seizures
66. Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings
67. Monoamine and GABA metabolism and the anticonvulsant action of di‐n‐propylacetate and ethanolamine‐O‐sulphate
68. In vivo studies into the effect of inhibition of rat brain succinic semialdehyde dehydrogenase on GABA synthesis and degradation
69. Effect of the anticonvulsant sodium valproate on aminobutyric and aldehyde metabolism in ox brain
70. Effect of acute and chronic anticonvulsant administration on endogenous γ‐hydroxybutyrate in rat brain
71. Anticonvulsant and brain aldehyde metabolism. Inhibitory characteristics of ox brain reductase
72. Slow wave sleep and a state resembling absence epilepsy induced in rats by γ‐hydroxybutyrate
73. Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake and metabolism of GABA
74. Biochemical and clinical effects of γ‐vinyl GABA in patients with epilepsy
75. Effect of sodium n‐dipropylacetate on audiogenic seizures and brain γ‐aminobutyric acid levels
76. Interactions of di‐n‐propylacetate, gabaculine and aminooxyacetic acid: anticonvulsant activity and the γ‐aminobutyrate system
77. The effect of sodium‐n‐dipropylacetate on γ‐aminobutyric acid‐dependent inhibition in the rat cortex and substantia nigra in relation to anticonvulsant activity
78. Differential effect of n‐dipropylacetate and amino‐oxyacetic acid on γ‐aminobutyric acid levels in discrete areas of rat brain
79. Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with anticonvulsant drugs diphenylhy‐dantoin, phenobarbitone, sodium valproate, ethosuximide and sulthiame in the rat
80. Dissociation between drug‐induced increases in nerve terminal and non‐nerve terminal pools of GABA in vivo.
81. Evaluation of increases in nerve terminal‐dependent vs nerve terminal‐independent compartments of GABA in vivo.
82. New directions in GABA research. I. Immunocytochemical studies of GABA neurons
83. Biochemical investigations into the mode of action of Na‐valproate and valprionic acid, respectively
84. Cerebrospinal fluid GABA in neurological disease
85. Increase in human plasma GABA by sodium valproate
86. The relationship between GABA concentrations in brain and cerebrospinal fluid
87. Seizure protection and increased nerve‐terminal GABA: delayed effect of GABA‐trans‐aminase inhibition
88. Effect of γ‐vinyl GABA on bicuculline‐induces seizures
89. Increased gamma‐aminobutyric acid (GABA), homocarnosine and β‐alanine in cerebrospinal fluid of patients treated with γ‐vinyl GABA (4‐amino‐hex‐5‐enoic acid)
90. Differential effect of gamma‐vinyl GABA and valproate on GABA‐transaminase from cultured neurones and astrocytes
91. Cell cultures
92. Differences in biochemical properties of γ‐aminobutyric acid aminotransferase from synaptosome‐enriched and cytoplasmatic mitochondria‐enriched subcellular fractions of mouse brain
93. Turnover of γ‐aminobutyrate amino‐transferase in some regions of rat brain
94. Stereoselective uptake of the GABA‐transaminase inhibitor gamma‐vinyl GABA and gamma‐acetylenic GABA into neurons and astrocytes
95. Changes in the turnover number of GABA‐T in cerebral cortex and in cultured cortical neurons during development
96. The release of γ‐aminobutyric acid during inhibition in the cat visual cortex
97. 3H]γ‐aminobutyric acid from brain slices
98. 14C]butyrate from synaptosomes: time course of stimulation by potassium, veratridine and the calcium ionophore A 23187
99. The action of γ‐vinyl GABA and γ‐acetylenic GABA on the resting and stimulated release of GABA in vivo.
100. Effect of γ‐acetylenic GABA and γ‐vinyl GABA on synaptosomal release and uptake of GABA
101. 3H]GABA from synaptosomal preparations using ion‐exchange chromatography
102. The effect of valproate, vigabatrin and amino‐oxyacetic acid on release of endogenous and exogenous GABA from cultured neurons
103. Sodium valproate, serum levels and clinical effect. A controlled study
104. Clinical pharmacological aspects of valproate sodium
105. Fluctuations of dipropyl acetate plasma levels with one and three daily doses
106. Human brain, plasma and cerebrospinal fluid concentrations of sodium valproate after 72 hours therapy
107. Gamma‐vinyl GABA: a single‐blind trial in patients with epilepsy
108. Double‐blind study of γ‐vinyl GABA in patients with refractory epilepsy
109. γ‐vinyl GABA: a double‐blind placebo‐controlled trial in partial epilepsy
110. Vigabatrin for refractory complex partial seizures: multicenter single‐blind study with long‐term follow‐up
111. Interrelationship between ornithine, glutamate and GABA. I. Feed‐back inhibition of ornithine aminotransferase by elevated brain GABA levels
112. Anticonvulsant action in mice with sound‐induced seizures of the optical isomers of γ‐vinyl GABA
113. The historical development of clinical therapeutic trials
114. Om serumbehandling af difteri
115. Streptomycin treatment of pulmonary tuberculosis
116. Controlled trials in epilepsy: a review
117. Le diazepam (Valium®) intravenieux dans le traitment des etats de epileptique. Une etude a double insu
118. A double‐blind comparison of nitrazepam versus diazepam in myoclonic seizure disorders
119. A double‐blind study of clonazepam in the treatment of therapy‐resistant epilepsy in children
120. Clonazepam in the treatment of petit mal
121. Clorazepate as an anticonvulsant
122. The effect of clonazepam upon epilepsy control and plasma levels of anticonvulsants
123. Ensayo de valoracion clinicoelectroen‐cephalografica de un nuevo derivade benzodiazepinico (RO 05‐4023) administracion oral en pacientes epilepticos con tecnica de doble ceguera
124. Tegretol (carbamazepine): a controlled trial of a new anticonvulsant
125. Carbamazepine: behavioural, anticonvulsant and EEG effects in chronically hospitalized epileptics
126. Car‐bamazepine ‐ a double‐blind comparison with phenytoin
127. Carbamazepine for epilepsy: a controlled prospective evaluation
128. Propietes antiepileptique et psychotropes de la carbamazepine (Tegretol)
129. Carbamazepine vs phenytoin
130. The effect of carbamazepine on patients with psychomotor epilepsy. Results of a double‐blind study
131. A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy
132. Effect of carbamazepine (Tegretol) on the electroencephalograph and ward behaviour of patients with chronic epilepsy
133. Evaluation of albutoin as an antiepileptic drug
134. Albutoin, a new thiohydantoin derivative for grand mal epilepsies
135. Postoperative epilepsy: a double‐blind trial of phenytoin after craniotomy
136. Eterobarb therapy in epilepsy
137. Valproate sodium: a controlled clinical trial including monitoring of serum levels
138. Doppelt‐blind Untersuchung über die anticonvulsive Wirkung von Phenobarbital und Valproat beim Lennox Syndrome
139. Controlled trial of sodium valproate in severe epilepsy
140. A double‐blind comparative trial of sodium dipropylacetate and ethosuximide in epilepsy in children with special emphasis on pure petit mal seizures
141. Sulthiame: evaluation as an anticonvulsant
142. Beclamide in intractable epilepsy: a controlled trial
143. Comparative trial of diazepam and pheneturide in the treatment of epilepsy
144. Relative anticonvulsant potency of primidone
145. The two‐period cross‐over clinical trial
146. Suitability and efficiency of cross‐over drug trial designs in epilepsy
147. Antiepileptic effect of clobazam in children
148. Development of tolerance to anticonvulsant effect of clobazam
149. Management of epilepsy with diphenylhydantoin sodium
150. Single‐drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect
151. Clinical and electroencephalographical classification of seizures
152. Mathematical model of patterns of seizures
153. Catamenial epilepsy: a review
154. Circadian cycles and seizures
155. Regression towards mediocrity in hereditary stature
156. A double‐blind crossover study of cinromide versus placebo in epileptic outpatients with partial seizures
157. Validation of the phenomenon of regression of seizure frequency in epilepsy
158. Simultaneous recording of absence seizures with video tape and electroencephalography
159. Comparison of alternative outcome measures for antiepileptic drug trials
160. Clonazepam (Rivotril®) and carbamazepine (Tegretol®) in psychomotor epilepsy: a randomized multicenter trial
161. Efficacy of sodium valproate in partial epilepsies. A cross‐over study of valproate vs carbamazepine
162. Vaiproate sodium: evaluation of so‐called psychotropic effect. A controlled study
163. Usefulness of blood levels of antiepileptic drugs
164. Paradoxical intoxication ‐ a complication of anticonvulsant administration
165. Clinical and electroencephalographic correlation with serum levels of diphenylhydantoin
166. Anticonvulsant effect of diphenylhydantoin relative to plasma levels
167. Remission of seizures and relapse in patients with epilepsy
168. Ethosuximide: relation of plasma levels to clinical control
169. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease
170. Valproic acid dosage and plasma protein binding and clearance
171. Serum‐phenytoin levels in the management of epilepsy
172. One drug for epilepsy
173. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy
174. Micro‐vacuolation in rat brains after long term administration of GABA‐transaminase inhibitors
175. Double‐blind, placebo‐controlled study of vigabatrin (gamma‐vinyl GABA) in drug‐resistant epilepsy
176. Vigabatrin in the treatment of epilepsy: a double‐blind, placebo‐controlled study
177. Controlled and comparative studies performed in Europe and Asia
178. Comparison of valproic acid and phenytoin in newly diagnosed tonic‐clonic seizures
179. Which drug for the adult epileptic patient: phenytoin or valproate
180. Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy
181. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal)
182. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy
183. Valproic acid versus ethosuximide in the treatment of absence seizures
184. Antiepileptic drug development program
185. Preclinial test systems for evaluation of novel compounds
186. Vigabatrin: no micro‐vacuoles in a human brain
187. Amino acid neurotransmitters and new approaches to anticonvulsant drug action
188. Anticonvulsant action of excitatory amino acid antagonists
189. Antiepileptic action of excitatory amino acid antagonists in the photosensitive baboon, Papio papio.
190. Lamotrigine: single‐dose pharmacokinetics and initial 1 week experience in refractory epilepsy
191. Seven day administration of lamotrigine in epilepsy: placebo‐controlled add‐on trial
192. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action
193. Proposal for classification of epilepsies and epileptic syndromes